AG
NKTR icon

Algert Global’s Nektar Therapeutics NKTR Stock Holding History

Algert Global’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.69M Buy
67,130
+32,348
+93% +$2.37M 0.06% 553
2026
Q1 		$2.5M Buy
34,782
+19,472
+127% +$1.11M 0.04% 655
2025
Q4 		$647K Buy
+15,310
New +$857K 0.01% 914
2025
Q2 		– Sell
-3,247
Closed -$33.1K – 1292
2025
Q1 		$33.1K Buy
+3,247
New +$42.4K ﹤0.01% 1156
2024
Q2 		– Sell
-1,962
Closed -$27.5K – 1565
2024
Q1 		$27.5K Sell
1,962
-1,840
-48% -$19.3K ﹤0.01% 1044
2023
Q4 		$32.2K Sell
3,802
-8,240
-68% -$62.4K ﹤0.01% 1109
2023
Q3 		$108K Hold
12,042
– – 0.01% 1024
2023
Q2 		$104K Buy
+12,042
New +$128K ﹤0.01% 1032
2023
Q1 		– Sell
-23,174
Closed -$786K – 1252
2022
Q4 		$786K Sell
23,174
-8,587
-27% -$416K 0.04% 659
2022
Q3 		$1.52M Buy
31,761
+2,894
+10% +$172K 0.09% 370
2022
Q2 		$1.65M Buy
28,867
+24,000
+493% +$1.51M 0.12% 260
2022
Q1 		$394K Buy
+4,867
New +$720K 0.03% 887
2015
Q3 		– Sell
-1,455
Closed -$273K – 334
2015
Q2 		$273K Buy
+1,455
New +$250K 0.15% 232

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Algert Global's NKTR Position: Q2 2026 in Review

Algert Global increased its Nektar Therapeutics (NKTR) stake by 93% in Q2 2026, buying an estimated $2.37M and bringing the position to 67,130 shares worth $4.69M. The position accounts for 0.06% of the portfolio, ranked #553.

Algert Global first reported a position in NKTR in Q2 2015 and has held it in 13 quarters since. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Algert Global held 67,130 shares of Nektar Therapeutics worth $4.69M as of Q2 2026.
  • Algert Global bought 32,348 Nektar Therapeutics shares in Q2 2026, an estimated $2.37M.
  • Nektar Therapeutics made up 0.06% of Algert Global's portfolio in Q2 2026, its #553 holding.
  • Algert Global first reported a position in Nektar Therapeutics in Q2 2015 and has held it in 13 quarters since.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.